Index -
P/E -
EPS (ttm) -2.45
Insider Own 39.47%
Shs Outstand 67.71M
Perf Week 19.12%
Market Cap 330.87M
Forward P/E -
EPS next Y -1.76
Insider Trans 0.48%
Shs Float 41.21M
Perf Month 61.46%
Income -165.87M
PEG -
EPS next Q -0.70
Inst Own 61.64%
Short Float 3.11%
Perf Quarter 153.13%
Sales 298.76M
P/S 1.11
EPS this Y -623.81%
Inst Trans -2.57%
Short Ratio 1.05
Perf Half Y 158.51%
Book/sh 3.84
P/B 1.27
EPS next Y 52.05%
ROA -42.22%
Short Interest 1.28M
Perf Year -70.46%
Cash/sh 4.55
P/C 1.07
EPS next 5Y -
ROE -51.22%
52W Range 1.58 - 19.95
Perf YTD -66.98%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -63.29%
52W High -75.64%
Beta -0.52
Dividend TTM -
Quick Ratio 4.66
Sales past 5Y 2300.59%
Gross Margin 53.30%
52W Low 208.57%
ATR (14) 0.42
Dividend Ex-Date Mar 28, 2018
Current Ratio 4.66
EPS Y/Y TTM -100.06%
Oper. Margin -51.85%
RSI (14) 77.08
Volatility 20.77% 10.04%
Employees 384
Debt/Eq 0.01
Sales Y/Y TTM 55.71%
Profit Margin -55.52%
Recom 2.33
Target Price 5.33
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -439.59%
Payout 0.00%
Rel Volume 6.08
Prev Close 4.53
Sales Surprise -109.59%
EPS Surprise -46.58%
Sales Q/Q -101.04%
Earnings Aug 08 BMO
Avg Volume 1.22M
Price 4.86
SMA20 33.59%
SMA50 66.13%
SMA200 -7.04%
Trades
Volume 1,055,342
Change 7.28%
Date
Action
Analyst
Rating Change
Price Target Change
Today Upgrade
BofA Securities
Neutral → Buy
$4.20 → $10
Mar-18-24 Downgrade
Mizuho
Buy → Neutral
$32 → $4
Mar-11-24 Downgrade
Robert W. Baird
Outperform → Neutral
$37 → $4
Mar-11-24 Downgrade
Leerink Partners
Outperform → Market Perform
$27 → $4
Mar-08-24 Downgrade
Goldman
Buy → Neutral
Mar-08-24 Downgrade
Evercore ISI
Outperform → In-line
Jan-03-24 Initiated
Robert W. Baird
Outperform
$37
Dec-12-23 Initiated
Deutsche Bank
Buy
$36
Jul-24-23 Upgrade
Goldman
Neutral → Buy
$45 → $49
Mar-31-23 Initiated
Mizuho
Buy
$52
Jan-05-23 Initiated
BofA Securities
Buy
$50
May-25-22 Initiated
Citigroup
Buy
$21
Apr-01-22 Downgrade
Goldman
Buy → Neutral
$36 → $10
Show Previous Ratings
Oct-19-24 11:12AM
Oct-18-24 07:34AM
(Clinical Trials Arena) +21.94%
07:26AM
07:04AM
Oct-17-24 09:00AM
09:00AM
Loading…
Oct-15-24 09:00AM
Oct-09-24 05:32PM
Sep-09-24 07:17PM
(GuruFocus.com) +6.33%
+5.56%
Sep-06-24 01:49AM
Aug-28-24 08:30AM
Aug-12-24 09:00AM
Aug-08-24 07:00AM
Aug-05-24 09:00AM
04:32AM
(Pharmaceutical Technology)
Aug-02-24 09:00AM
10:53AM
Loading…
Jul-10-24 10:53AM
(Clinical Trials Arena) +25.45%
07:00AM
03:00AM
Jul-09-24 04:01PM
Jun-28-24 11:02AM
(Pharmaceutical Technology)
Jun-04-24 09:00AM
May-14-24 07:25AM
May-10-24 03:54PM
12:47PM
May-09-24 08:15AM
07:00AM
May-08-24 09:00AM
May-02-24 09:00AM
Apr-30-24 12:02PM
Apr-10-24 03:14PM
09:00AM
Loading…
09:00AM
Apr-08-24 09:00AM
Apr-04-24 01:20PM
10:05AM
(Associated Press Finance)
07:52AM
07:43AM
07:07AM
07:00AM
06:09AM
Apr-03-24 05:45AM
Apr-01-24 07:30PM
Mar-27-24 07:36AM
Mar-25-24 02:33PM
Mar-14-24 06:49PM
09:00AM
Mar-13-24 10:00AM
09:03AM
Mar-12-24 07:55AM
Mar-11-24 12:34PM
07:45AM
Mar-10-24 08:00AM
(The Wall Street Journal)
Mar-08-24 06:27PM
(Business Wire) -82.29%
+13.10%
04:05PM
(Investor's Business Daily)
11:30AM
(Associated Press Finance)
10:20AM
10:12AM
(Investor's Business Daily)
09:38AM
09:26AM
07:07AM
07:00AM
02:05AM
Feb-27-24 05:45AM
Feb-26-24 11:39AM
Feb-25-24 06:30AM
Feb-23-24 04:05PM
10:30AM
10:10AM
09:00AM
05:45AM
Feb-22-24 06:57PM
04:10PM
(Investor's Business Daily)
08:15AM
07:35AM
07:00AM
Feb-20-24 05:45AM
Feb-19-24 12:40PM
Feb-15-24 04:05PM
02:13PM
09:00AM
Feb-13-24 09:16PM
12:58PM
Feb-12-24 08:09PM
11:09AM
Feb-08-24 09:00AM
Jan-26-24 03:57PM
Jan-21-24 01:16PM
Jan-14-24 12:54PM
Jan-05-24 05:34AM
Dec-26-23 07:02PM
08:48AM
Dec-22-23 09:00AM
Dec-11-23 08:36AM
Dec-04-23 09:00AM
Nov-29-23 05:15PM
Nov-28-23 08:48AM
07:00AM
Nov-27-23 09:00AM
Nov-21-23 09:00AM
Nov-12-23 11:59AM
Nov-10-23 12:26AM
(Thomson Reuters StreetEvents)
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Klee Justin B. Co-Chief Executive Officer Sep 30 '24 Sale 3.20 18,589 59,429 3,120,569 Oct 02 06:53 PM Cohen Joshua B Co-Chief Executive Officer Sep 30 '24 Sale 3.20 18,589 59,414 3,220,569 Oct 02 06:53 PM Bedrosian Camille L Chief Medical Officer Sep 30 '24 Sale 3.20 11,442 36,559 143,801 Oct 02 06:50 PM Mazzariello Gina Chief Legal Officer Sep 30 '24 Sale 3.20 8,709 27,840 142,768 Oct 02 06:48 PM Cohen Joshua B Co-Chief Executive Officer Sep 23 '24 Option Exercise 1.57 1,857 2,915 3,239,158 Sep 25 05:56 PM Cohen Joshua B Co-Chief Executive Officer Sep 12 '24 Option Exercise 1.57 34,449 54,085 3,237,301 Sep 16 05:39 PM FRATES JAMES M Chief Financial Officer Sep 12 '24 Buy 2.53 40,000 101,368 233,464 Sep 16 05:30 PM Firestone Karen Director Sep 05 '24 Buy 2.13 50,000 106,590 55,000 Sep 09 04:05 PM MILNE GEORGE M JR Director Sep 03 '24 Buy 2.20 100,000 219,800 858,571 Sep 05 07:26 PM Quimi Daphne Director May 14 '24 Buy 1.89 2,750 5,184 2,750 May 16 07:37 PM Quimi Daphne Director May 15 '24 Buy 1.89 2,250 4,252 5,000 May 16 07:37 PM Mazzariello Gina Chief Legal Officer May 15 '24 Sale 1.88 10,455 19,654 151,477 May 16 07:36 PM Cohen Joshua B Co-Chief Executive Officer Mar 05 '24 Sale 18.73 4,135 77,440 3,023,002 Mar 07 04:05 PM Klee Justin B. Co-Chief Executive Officer Mar 05 '24 Sale 18.73 4,135 77,440 2,959,308 Mar 07 04:05 PM FRATES JAMES M Chief Financial Officer Mar 05 '24 Sale 18.73 1,792 33,560 134,784 Mar 07 04:05 PM Mazzariello Gina Chief Legal Officer Mar 05 '24 Sale 18.73 1,540 28,841 81,372 Mar 07 04:05 PM Mazzariello Gina Chief Legal Officer Feb 23 '24 Sale 18.76 2,838 53,231 46,245 Feb 27 05:59 PM Klee Justin B. Co-Chief Executive Officer Jan 09 '24 Sale 16.33 5,841 95,372 2,836,776 Jan 11 05:11 PM FRATES JAMES M Chief Financial Officer Jan 09 '24 Sale 16.33 2,716 44,347 112,035 Jan 11 05:11 PM Cohen Joshua B Co-Chief Executive Officer Jan 09 '24 Sale 16.33 5,841 95,372 2,900,470 Jan 11 05:10 PM Yeramian Patrick D Chief Medical Officer Jan 09 '24 Sale 16.33 2,812 45,915 205,605 Jan 11 05:04 PM Olinger Margaret Chief Commercial Officer Dec 27 '23 Option Exercise 0.37 25,000 9,250 276,108 Dec 29 04:07 PM Firestone Karen Director Dec 15 '23 Buy 14.97 4,000 59,880 5,000 Dec 19 04:37 PM Cohen Joshua B Co-Chief Executive Officer Nov 16 '23 Option Exercise 1.57 63,694 100,000 2,906,311 Nov 20 08:20 PM
Index -
P/E -
EPS (ttm) -7.29
Insider Own 6.46%
Shs Outstand 92.17M
Perf Week -2.94%
Market Cap 5.16B
Forward P/E -
EPS next Y -5.28
Insider Trans -1.00%
Shs Float 86.21M
Perf Month -2.57%
Income -585.12M
PEG -
EPS next Q -1.48
Inst Own 96.70%
Short Float 3.35%
Perf Quarter 24.28%
Sales 481.30M
P/S 10.72
EPS this Y 22.42%
Inst Trans 10.70%
Short Ratio 4.26
Perf Half Y 26.47%
Book/sh 4.70
P/B 11.92
EPS next Y 17.55%
ROA -39.94%
Short Interest 2.89M
Perf Year 75.01%
Cash/sh 8.35
P/C 6.70
EPS next 5Y 37.90%
ROE -208.43%
52W Range 31.52 - 60.37
Perf YTD 17.11%
Dividend Est. -
P/FCF -
EPS past 5Y -15.75%
ROI -45.00%
52W High -7.24%
Beta 0.57
Dividend TTM -
Quick Ratio 3.39
Sales past 5Y 63.06%
Gross Margin 83.47%
52W Low 77.67%
ATR (14) 1.69
Dividend Ex-Date -
Current Ratio 3.54
EPS Y/Y TTM 28.85%
Oper. Margin -114.03%
RSI (14) 52.37
Volatility 2.71% 3.05%
Employees 1276
Debt/Eq 2.14
Sales Y/Y TTM 19.47%
Profit Margin -121.57%
Recom 1.20
Target Price 92.10
Option/Short Yes / Yes
LT Debt/Eq 2.01
EPS Q/Q 32.57%
Payout -
Rel Volume 0.50
Prev Close 54.79
Sales Surprise 19.34%
EPS Surprise 8.47%
Sales Q/Q 35.75%
Earnings Aug 01 AMC
Avg Volume 677.50K
Price 56.00
SMA20 1.63%
SMA50 0.20%
SMA200 17.60%
Trades
Volume 48,541
Change 2.21%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-06-24 Upgrade
Goldman
Neutral → Buy
$56 → $67
Apr-22-24 Initiated
RBC Capital Mkts
Outperform
$77
Dec-08-23 Initiated
Wells Fargo
Overweight
$72
Jun-14-23 Resumed
Credit Suisse
Outperform
$96
Jun-06-23 Upgrade
Evercore ISI
In-line → Outperform
$60 → $80
Apr-26-23 Initiated
Cantor Fitzgerald
Overweight
$114
Jan-18-23 Resumed
Canaccord Genuity
Buy
$90
Dec-30-22 Resumed
H.C. Wainwright
Buy
$82
Nov-03-22 Upgrade
Robert W. Baird
Neutral → Outperform
$50
Oct-13-22 Upgrade
Guggenheim
Neutral → Buy
$50
Aug-01-22 Downgrade
Evercore ISI
Outperform → In-line
$95 → $60
Mar-16-22 Upgrade
Credit Suisse
Neutral → Outperform
$99 → $105
Feb-11-22 Upgrade
JP Morgan
Neutral → Overweight
$132
Sep-30-21 Initiated
H.C. Wainwright
Buy
$106
Aug-19-21 Initiated
UBS
Sell
$73
Jul-15-21 Initiated
Guggenheim
Neutral
Jun-29-21 Upgrade
BofA Securities
Neutral → Buy
$162
Jun-04-21 Resumed
Robert W. Baird
Neutral
$109
May-06-21 Upgrade
Evercore ISI
In-line → Outperform
$144
May-06-21 Upgrade
Citigroup
Neutral → Buy
$160 → $151
Show Previous Ratings
Oct-18-24 04:30PM
Oct-07-24 08:00AM
Oct-03-24 04:30PM
Sep-26-24 08:00AM
Sep-18-24 05:00PM
01:07AM
Loading…
Sep-05-24 01:07AM
Sep-02-24 06:05PM
Aug-29-24 04:30PM
Aug-21-24 04:30PM
Aug-06-24 10:45AM
Aug-02-24 08:15AM
07:44AM
Aug-01-24 04:17PM
(Associated Press Finance)
04:05PM
Jul-25-24 04:05PM
08:00AM
Loading…
Jul-24-24 08:00AM
Jul-22-24 04:27PM
(Investor's Business Daily)
Jul-19-24 04:05PM
Jul-18-24 09:03AM
Jul-17-24 04:05PM
Jun-20-24 04:30PM
Jun-17-24 03:27PM
Jun-13-24 08:49PM
10:15AM
05:12AM
03:14AM
Jun-12-24 04:05PM
04:00PM
10:46AM
07:45AM
05:47PM
Loading…
Jun-11-24 05:47PM
Jun-04-24 04:05PM
May-31-24 10:36AM
May-30-24 04:00PM
May-22-24 02:27PM
May-17-24 04:30PM
May-07-24 04:30PM
May-04-24 10:24AM
May-03-24 03:01PM
12:22PM
May-02-24 08:58PM
08:00PM
05:49PM
05:10PM
04:08PM
(Associated Press Finance)
04:00PM
Apr-30-24 04:00PM
08:00AM
Apr-25-24 04:30PM
Apr-19-24 04:30PM
Apr-16-24 11:33AM
Apr-15-24 07:30AM
07:00AM
Apr-12-24 04:22PM
08:00AM
Mar-22-24 04:00PM
Mar-20-24 08:11AM
Mar-12-24 05:00PM
Mar-11-24 03:00PM
Mar-08-24 09:38AM
Feb-27-24 04:30PM
Feb-23-24 04:05PM
Feb-16-24 10:43AM
10:35AM
(Thomson Reuters StreetEvents)
07:53AM
Feb-15-24 04:15PM
(Associated Press Finance)
04:01PM
Feb-13-24 01:36PM
Feb-08-24 04:00PM
Feb-06-24 08:00AM
Feb-05-24 04:05PM
Jan-25-24 04:05PM
Jan-19-24 04:00PM
Jan-18-24 02:41PM
(Investor's Business Daily)
Jan-09-24 06:20PM
Jan-08-24 12:18PM
07:00AM
Jan-07-24 11:00AM
Jan-04-24 08:12AM
08:00AM
Jan-03-24 08:00AM
Jan-02-24 04:05PM
Dec-27-23 06:41PM
Dec-21-23 05:21PM
(The Wall Street Journal)
04:30PM
Dec-18-23 09:29AM
08:00AM
Dec-15-23 10:18AM
Nov-20-23 04:30PM
Nov-17-23 04:30PM
Nov-07-23 05:00PM
Nov-04-23 01:12PM
12:16PM
Nov-03-23 11:43AM
Nov-02-23 06:26PM
04:36PM
(Associated Press Finance)
04:05PM
Oct-26-23 04:05PM
Oct-25-23 06:17AM
Oct-23-23 04:01PM
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Horn Howard Chief Financial Officer Oct 10 '24 Sale 52.76 7,465 393,853 92,301 Oct 11 04:48 PM KAKKIS EMIL D President & CEO Sep 03 '24 Sale 55.85 20,000 1,117,000 2,223,985 Sep 05 11:53 AM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 03 '24 Sale 56.19 91 5,113 41,551 Sep 05 11:50 AM KAKKIS EMIL D Officer Sep 03 '24 Proposed Sale 55.85 20,000 1,117,096 Sep 03 04:40 PM KAKKIS EMIL D President & CEO Aug 06 '24 Sale 50.17 20,000 1,003,400 2,243,985 Aug 07 02:48 PM KAKKIS EMIL D Officer Aug 06 '24 Proposed Sale 50.17 20,000 1,003,418 Aug 06 04:28 PM Sanders Corazon (Corsee) D. Director Jul 02 '24 Sale 40.98 584 23,932 12,009 Jul 03 02:07 PM Parschauer Karah Herdman EVP and Chief Legal Officer Jun 12 '24 Sale 45.00 9,806 441,270 57,981 Jun 12 07:47 PM Sanders Corazon (Corsee) D. Director Jun 10 '24 Sale 41.10 1,737 71,391 7,248 Jun 10 07:58 PM Crombez Eric EVP and Chief Medical Officer May 02 '24 Sale 43.66 354 15,456 48,431 May 03 03:23 PM Crombez Eric EVP and Chief Medical Officer Apr 18 '24 Sale 44.10 142 6,262 48,785 Apr 19 04:35 PM Kassberg Thomas Richard CBO & EVP Mar 11 '24 Sale 49.93 11,509 574,644 252,823 Mar 12 01:41 PM Fust Matthew K Director Mar 07 '24 Sale 50.88 12,195 620,443 14,860 Mar 11 12:54 PM Parschauer Karah Herdman EVP and Chief Legal Officer Mar 01 '24 Sale 53.76 3,756 201,923 67,340 Mar 05 08:22 PM Kassberg Thomas Richard CBO & EVP Mar 01 '24 Sale 53.76 1,011 54,351 264,332 Mar 05 08:19 PM Pinion John Richard See Remarks Mar 01 '24 Sale 53.76 4,173 224,340 89,268 Mar 05 08:15 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Mar 01 '24 Sale 53.76 341 18,332 41,380 Mar 05 08:13 PM Crombez Eric EVP and Chief Medical Officer Mar 01 '24 Sale 53.76 1,238 66,555 48,927 Mar 05 08:10 PM Harris Erik EVP & Chief Commercial Officer Mar 01 '24 Sale 53.76 4,768 256,328 67,163 Mar 05 08:08 PM KAKKIS EMIL D President & CEO Feb 07 '24 Sale 45.00 30,000 1,350,000 539,770 Feb 08 03:49 PM KAKKIS EMIL D President & CEO Dec 29 '23 Sale 47.87 30,000 1,436,100 569,770 Jan 02 04:07 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Jan 02 '24 Option Exercise 21.00 3,000 63,000 27,892 Jan 02 04:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite